11 research outputs found
Antimycobacterial activity of peptide conjugate of pyridopyrimidine derivative against Mycobacterium tuberculosis in a series of in vitro and in vivo models
New pyridopyrimidine derivatives were defined using a novel HTS in silico docking method
(FRIGATE). The target protein was a dUTPase enzyme (EC 3.6.1.23; Rv2697) which plays a key
role in nucleotide biosynthesis of Mycobacterium tuberculosis (Mtb). Top hit molecules were
assayed in vitro for their antimycobacterial effect on Mtb H37Rv culture. In order to enhance the
cellular uptake rate, the TB820 compound was conjugated to a peptid-based carrier and a
nanoparticle type delivery system (polylactide-co-glycolide, PLGA) was applied. The conjugate had
relevant in vitro antitubercular activity with low in vitro and in vivo toxicity. In a Mtb H37Rv
infected guinea pig model the in vivo efficacy of orally administrated PLGA encapsulated
compound was proved: animals maintained a constant weight gain and no external clinical signs of
tuberculosis were observed. All tissue homogenates from lung, liver and kidney were found
negative for Mtb, and diagnostic autopsy showed that no significant malformations on the tissues
occurred
Recommended from our members
Design and Characterization of a Multistage Peptide-Based Vaccine Platform to Target Mycobacterium tuberculosis Infection.
The complex immunopathology ofMycobacterium tuberculosis(Mtb) is one of the main challenges in developing a novel vaccine against this pathogen, particularly regarding eliciting protection against both active and latent stages. Multistage vaccines, which contain antigens expressed in both phases, represent a promising strategy for addressing this issue, as testified by the tuberculosis vaccine clinical pipeline. Given this approach, we designed and characterized a multistage peptide-based vaccine platform containing CD4+ and CD8+ T cell epitopes previously validated for inducing a relevant T cell response against Mtb. After preliminary screening, CFP10 (32-39), GlfT2 (4-12), HBHA (185-194), and PPE15 (1-15) were selected as promising candidates, and we proved that the PM1 pool of these peptides triggered a T cell response in Mtb-sensitized human peripheral blood mononuclear cells (PBMCs). Taking advantage of the use of thiol-maleimide chemoselective ligation, we synthesized a multiepitope conjugate (Ac-CGHP). Our results showed a structure-activity relationship between the conjugation and a higher tendency to fold and assume an ordered secondary structure. Moreover, the palmitoylated conjugate (Pal-CGHP) comprising the same peptide antigens was associated with an enhanced cellular uptake in human and murine antigen-presenting cells and a better immunogenicity profile. Immunization study, conducted in BALB/c mice, showed that Pal-CGHP induced a significantly higher T cell proliferation and production of IFNγ and TNFα over PM1 formulated in the Sigma Adjuvant System